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Abstract
Background: Hematological abnormalities are a common complication of HIV infection. These
abnormalities increase as the disease advances. Bone marrow abnormalities occur in all stages of
HIV infection.
Methods: Two hundred HIV infected individual were screened for hematological abnormalities
from March 2007–March 2008. Absolute CD4 cell count analysis was carried out by
flowcytometry. Depending on the results of the primary screening further investigations were
performed, like iron studies, hemolytic work up, PNH work up and bone marrow evaluation.
Other investigations included coagulation profile, urine analysis, blood culture (bacterial, fungal,
mycobacterial), serology for Epstein Barr virus (EBV), Cytomegalovirus (CMV), Hepatitis B and C,
and Parvo B19 infection.
Results: The most common hematological abnormality was anemia, seen in 65.5% (131/200)
patients. Iron deficiency anemia was seen in 49.2% (/200) cases while anemia of chronic disease
occurred in 50.7% (/200) cases. Bone marrow evaluation was carried out in 14 patients out of
which staging marrow was performed in 2 cases of non-Hodgkin's lymphoma (NHL) and did not
show any bone marrow infiltration. In remaining12 cases bone marrow was done for evaluation of
pancytopenia. Among patients with pancytopenia 50% (6/12) showed granulomas (4 were positive
for AFB, 2 were positive for fungal cryptococci), 25% (3/12) showed hemophagocytosis. There was
a strong negative correlation between anemia and CD4 counts in this study. Thrombocytopenia
was seen in 7% (14/200) cases and had no significant correlation with CD4 counts. No patient had
absolute neutrophil count (ANC) < 800 cells/μL. No case of coagulation abnormalities was found.
Conclusion: Anemia in HIV patients can be a good clinical indicator to predict and access the
underlying immune status. Patients should be investigated for hematological manifestations and
appropriate steps should be taken to identify and treat the reversible factors.
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Background
Hematological abnormalities are among the most com-
mon complications of HIV. These involve all lineages of
blood cells [1]. HIV associated hematological abnormali-
ties seem to be dependent on the level of virus replication,
as these abnormalities are severe in late-stage AIDS
patients with high viremia. The mechanism underlying
these abnormalities is still obscure. A specific diagnosis of
the cause and mechanism must be sought because specific
treatment may be needed for its correction [1].
Anemia is the most common hematological abnormality
in HIV seropositive patients and its incidence is strongly
associated with the progression of the disease. Neutrope-
nia is common in the advanced stages of AIDS and often
caused or exacerbated by concomitant myelosuppressive
drugs. Adverse drug reactions and their complications can
cause neutropenia in patients with HIV/AIDS. Thrombo-
cytopenia is correlated with low CD4 cell count and older
age [2-4]. Bone marrow abnormalities are found in all
stages of HIV disease, increasing in frequency as the dis-
ease progresses. A number of characteristic but nonspe-
cific, morphologic abnormalities of the bone marrow of
AIDS patients have been reported [5]. Bone marrow exam-
ination may be useful for the definitive assessment of iron
stores which can assist in the differentiation of iron-defi-
ciency anemia from anemia of chronic disease. There is
paucity of data from India on the hematological manifes-
tations of HIV which prompted us to conduct this study.
We systematically assessed 200 HIV infected individuals
attending immunodeficiency clinic, PGIMER, to look for
various hematological manifestations.
Methods
Two hundred HIV seropositive consecutive individuals
were enrolled from the Immunodeficiency Clinic of Inter-
nal Medicine Department of Post Graduate Institute of
Medical Education & Research (PGIMER), at Chandigarh
between March 2007 to March 2008. Written informed
consent was obtained from all. Patients were excluded if
they refused to become part of study, were of less than 16
years of age or were pregnant.
Detailed history, general and systemic examination was
carried out with emphasis on signs suggesting hematolog-
ical system involvement like pallor, jaundice, edema, lym-
phadenopathy, koilonychias, angular cheilitis, glossitis,
ecchymosis/purpura, sternal tenderness, hepatosplenom-
egaly and peripheral neuritis.
The investigations included complete hemogram with
peripheral blood picture, complete biochemistry.
Depending on the results of the primary screening further
investigations were carried out – like iron studies, hemo-
lytic work up, Paroxysmal nocturnal hemoglobinuria
(PNH) work up and bone marrow study. Other investiga-
tions included coagulation profile, urine analysis, blood
culture (bacterial, fungal, mycobacterial), serology for
EBV, CMV, Parvo B19) and viral markers (HBSAg & Anti
HCV). Absolute CD4 cell count analysis was carried out
by flowcytometry. All 200 patients had been divided into
two groups, those having CD4 counts less than 200 cells/
μL (Group 1) and those with CD4 counts more than 200
cells/μL (Group 2).
Anemia was defined as hemoglobin <13 g/dl (Men) and
<12 g/dl (women). Leucopenia was defined as total WBC
count less than 4000 cells/μl. Neutropenia was defined as
absolute neutrophil count <1000 cells/μl. Lymphopenia
was considered when absolute lymphocyte count <800
cells/μl. Thrombocytopenia was defined as total platelet
count < 150 × 103/μl [6-8].
Bone marrow study
Bone marrow study was carried out in case of non-
responding anemia, thrombocytopenia, pancytopenia
and suspected hematological malignancy. As per indica-
tions of bone marrow study, posterior superior iliac spine
was the site for bone marrow aspiration and biopsy. Bone
marrow smears were stained with May Grunwald's-
Geimsa stain and examined by a hematopathologist.
Bone marrow samples were carefully evaluated for cellu-
larity, differential counts, dysplastic changes, fibrosis,
granulomas, organisms and iron stores. Special stains
were done whenever indicated which included cytochem-
ical stains like myeloperoxidase (MPO), periodic acid
schiff's (PAS), perl's and leucocyte alkaline phospatase
(LAP) stain. Reticulin stain on trephine biopsy was also
performed. The bone marrow aspirates were sent for bac-
terial, fungal and AFB cultures.
Statistical analysis
Descriptive statistics was expressed as mean ± SD (Range).
Comparisons between data were done by Student's t test
and chi-square test. A p value < 0.05 was taken as statisti-
cally significant.
The study was carried out after obtaining permission from
the Institute's Ethics Committee.
Results
The mean age of 200 HIV infected individual was 36.6 ±
8.7 yrs. One hundred eighty seven (93.5%) patients were
infected due to unprotected heterosexual exposure. About
two third of individuals, 67.5% (n = 135) were males and
32.5% (n = 65) were females. One hundred sixty five indi-
viduals were symptomatic and 35 were asymptomatic.
Symptomatic patients presented with fever (54.5%, n =
90), generalized weakness (18.1%, n = 30), diarrhea
(10.3%, n = 17), loss of weight/appetite (10.3%, n = 17)BMC Blood Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2326/9/5
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and others (6.6%, n = 11) with non specific symptoms.
Out of 165 symptomatic patients, 137 patients had more
than one symptom. Table 1 summarizes the results of
hematological parameters evaluated in 200 HIV infected
individuals. Table 2 shows the comparison between
parameters and CD4 counts in asymptomatic and symp-
tomatic groups. Mean CD4 cell count was 202.4 ± 182
cells/μL (range 8–1078 cells/μL). Sixty six individuals
(33%) were receiving ART while 134 (67%) were not
receiving ART.
Laboratory analysis
Anemia was found in 131 (65.5%) individuals and iron
studies were done in 126. Of these 131 individuals, 92.3%
(n = 121) were in Group 1, while 7.7% (n = 10) were in
Group 2. Hemoglobin (Hb), Packed cell volume (PCV),
Mean Cell Volume (MCV), Mean corpuscular hemo-
globin (MCH), Mean corpuscular hemoglobin concentra-
tion (MCHC) (p < 0.001) and serum ferritin (p < 0.05)
showed statistically significant correlation with CD4
counts and other parameters did not have significant cor-
relation with CD4 counts (Table 3).
Bone marrow abnormalities
Out of 200 patients, bone marrow aspiration was carried
out in 14 (7%) individuals. Among 14 patients, two
patients had non Hodgkin's lymphoma and remaining 12
patients were evaluated for pancytopenia. Six each had
(42.8%, n = 6) hypocellular marrow and hypercellular
marrow while 14.2% (n = 2) had normocellular marrow
(14.2%). Among 12 patients with pancytopenia, bone
marrow trephine biopsy revealed epithelioid cell granulo-
Table 1: Comparison of Baseline parameters in HIV infected males & females
PARAMETER MALE (MEAN ± S.D.)
N = 135
FEMALE 
(MEAN ± S.D.)
N = 65
TOTAL
(MEAN ± S.D.)
N = 200
P value Institute reference 
values*
AGE(yrs) 37.4 ± 8.25(18–60) 35.11 ± 9.66(18–60) 36.66 ± 8.75(18–60) 0.083
Hb (gm/dl) 10.58 ± 2.88(5.1–15.8) 9.8 ± 2.22(6.2 – 14.2) 10.3 ± 2.7(5.1–15.8) 0.081 12–18
PCV% 37.8 ± 7.4(20 – 68.4) 35.9 ± 6.7(23.6–46.6) 37.2 ± 7.2(20–68.4) 0.083 36–54
MCV(fl) 81.3 ± 8.3(62.5–103.3) 77.7 ± 7.6(62.4–94) 80.1 ± 8.3(62.4–03.3) 0.003 80–96
MCH(pg/cell) 26.3 ± 4.3(18.2–36.1) 24.2 ± 4.1(18.4 – 32.8) 25.6 ± 4.4(18.2–36.1) 0.001 27–32
MCHC% 32.2 ± 2.7(26.9–38.4) 31 ± 2.7(26.5 – 37.0) 31.8 ± 2.7(26.5–38.4) 0.005 30–36
TLC(cells/μl) 6985 ± 2740
(2200–16,000)
6715 ± 2481
(2800–16,000)
6898 ± 2655
(2200–16,000)
0.501 4000–11000
ANC(cells/μl) 4743 ± 2090(1012–2848) 4743 ± 2090
(2240–11700)
4696 ± 2052
(1012–12848)
0.637
ALC(cells/μl) 1778 ± 740(460–4200) 1722 ± 676(392–3680) 1759 ± 719(392–4200) 0.606
PLATELETS(×103 μl) 235.1 ± 105.8(16–685) 249.5 ± 913.5(13.6–495) 239.8 ± 101.3(13.6–685) 0.348 150–400
RETIC% 1.1 ± 0.8(0.4–5.5) 1.2 ± 0.9(0.4 – 4.2) 1.17 ± 0.87(0.5–5.5) 0.318 0.2–2.0
S. IRON(μg/dl) 76.7 ± 54.2(14 – 266) 56.1 ± 46.7(14–223) 69.5 ± 52.5(14–266) 0.035
TIBC(μg/dl) 396.3 ± 117.4(155 – 838) 404.6 ± 100.2(249–670) 399.2 ± 111.3(155–838) 0.692
S. FERRITIN(μg/dl) 522.7 ± 464.5(10–1500) 232.6 ± 328.8(5–1420) 421 ± 443(5–1500) 0.001
SATURATION% 20.3 ± 14.2(3.1–79) 14.5 ± 12.7(2.8–72.6) 18.3 ± 13.9 0.001
CD4 COUNTS(cells/μL) 187.2 ± 151.1(8–785) 233.8 ± 231.8(19–1078 202.4 ± 182 (8–1078) 0.090
*Institutional reference values have been provided by a personal Communication with Dr Man Updesh Singh Sachdeva, Department of Hematology, 
PGIMER, Chandigarh, India.BMC Blood Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2326/9/5
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mas in 6 cases (4 were positive for AFB, 2 were positive for
fungal profiles, morphologically and cytochemically con-
sistent with cryptococci), 3 cases showed hemophagocy-
tosis and 3 cases showed no specific pathology. Staging
marrow carried out in two patients with lymphoma
(NHL) did not show any infiltration of lymphoma cells.
Discussion and Conclusion
Hematological complications are a common cause of
mortality in HIV infected patients. Cytopenias are most
frequent during the advanced stage of disease [1]. We eval-
uated various hematological manifestations on 200 con-
secutive HIV seropositive patients who presented to the
Immunodeficiency clinic PGIMER, Chandigarh, irrespec-
tive of their ART status. We also correlated the final hema-
tological diagnosis of the patients with the CD4 count.
Anemia was the most common presentation. Among 200
individuals, 131 (65.5%) were found to be anemic out of
which 4 (3%) cases were in asymptomatic group and 127
(97%) were in symptomatic group (p < 0.001). Our
results on prevalence of anemia showed comparable
results with other studies from India [9-11]. In a study by
Mir et al on a cohort of 60 HIV infected individuals
reported anemia, thrombocytopenia, leucopenia and var-
ious permutations of these in majority of individuals [12].
The highest rate of anemia occurs in patients with
advanced HIV disease. In our study out of 131 patients,
92.4% (n = 121) cases were those with CD4 counts <200
cells/μL, while 7.6% (n = 10) patients were those with
CD4 counts >200 cells/μL and there was statistically sig-
nificant difference (p < 0.001) between both the groups.
Severe anemia (defined as hemoglobin less than 7.5 gm/
dl) was observed in 18.5% (n = 37) patients as compared
to 7% in a study by Kasthuri et al [9].
The cumulative incidence of anemia was highest among
patients who had CD4 lymphocyte count < 200 cells/μL
and was lowest with CD4 lymphocyte count > 500 cells/
μL, showing an inverse correlation between anemia and
Table 2: Comparison between parameters and CD4 counts between asymptomatic and symptomatic groups
PARAMETERS Asymptomatic
(n = 35)
Symptomatic
(n = 165)
p value TOTAL
AGE (yrs) 36.8 ± 9.6 (22–60) 36.6 ± 8.5 (18–60) 0.864 36.66 ± 8.75 (18–60)
BMI 20.4 ± 1.8 (16–27) 19.6 ± 1.7 (15–27) 0.001 20.68 ± 1.8 (15–27)
Hb (gm/dl) 13.3 ± 1.5 (9.4–15.8) 9.7 ± 2.4 (5.1–14.5) < 0.001 10.3 ± 2.7 (5.1–15.8)
PCV % 43.4 ± 2.5 (38.3–48.6) 35.9 ± 7.2 (20–68.4) < 0.001 37.2 ± 7.2 (20–68.4)
MCV (fl) 85.7 ± 4.5 (67.3–95) 79 ± 8.4 (62.4–103.3) < 0.001 80.1 ± 8.3 (62.4–103.3)
MCH (pg/cell) 28.4 ± 2.2 (18.8–32.6) 25.1 ± 4.5 (18.2–36.1) < 0.001 25.6 ± 4.4 (18.2–36.1)
MCHC % 33.1 ± 0.01 (27.9–36) 31.5 ± 0.2 (26.5–38.4) 0.002 31.8 ± 2.7 (26.5–38.4)
TLC (cells/μl) 6560 ± 1413 (4300–10,700) 6969 ± 2848 (2200–16,000) 0.409 6898 ± 2655 (2200–6,000)
ANC (cells/μl) 4312 ± 962 (2580–5166) 4777 ± 2209 (1012–12848) 0.224 4696 ± 2052 (1012–12848)
ALC (cells/μl) 1800 ± 484 (1024–2940) 1751 ± 760 (392–4200) 0.713 1759 ± 719 (392–4200)
PLATELETS (×103/μl) 248.6 ± 845.7 (150–417) 237.9 ± 104.6 (13.6–685) 0.574 239.8 ± 101.3 (13.6–685)
RETIC % 1 ± 0.4 (0.5–3.4) 1.1 ± 0.9 (0.4–5.5) 0.415 1.17 ± 0.87 (0.5–5.5)
S. IRON (μg/dl) 64.2 ± 36.0 (33–110) 69.7 ± 53.0 (14–266) 0.839 69.5 ± 52.5 (14–266)
TIBC (μg/dl) 479.2 ± 217.7 (292–752) 396.6 ± 106.8 (155–838) 0.145 399.2 ± 111.3 (155–838)
S. FERRITIN (μg/dl) 553.2 ± 545.3 (5–1280) 417 ± 441.3 (5–1500) 0.547 421 ± 443 (5–1500)
CD4 COUNTS (cells/μl) 386.6 ± 214.3 (65–1078) 163.3 ± 148 (8–967) < 0.001 202.4 ± 182 (8–1078)BMC Blood Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2326/9/5
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CD4 cell count (p < 0.001). HIV infected individuals with
anemia are at increased risk for progression to AIDS and
mortality, recovery from anemia has been associated with
a decreased risk of deaths. We did not estimate the sur-
vival in patients with and without anemia, as this was a
descriptive study, though the literature clearly indicates
that it does affect the survival [13].
The hemoglobin, PCV, MCV, MCH, and MCHC showed
statistically significant correlation with CD4 counts (p <
0.001) in both males and females. Iron studies were done
in 126 patients out of which 65.1% (n = 82) were males
and 34.9% (n = 44) were females. Iron deficiency anemia
was found in 49.2% cases (n = 62; 34 males, 28 females).
Anemia of chronic disease was found in 50.8% cases (n =
64; 48 males, 16 females) among which 2 males showed
macrocytosis with MCV >100, a possibility of coexisting
megaloblastic anemia could not be ruled out as serum
vitamin B12/folic acid level was not done. Among
patients with anemia 25.9% (34/131) males and 21.3%
(28/131) females had iron deficiency anemia, while
36.6% (48/131) males and 12.2% (16/131) females had
anemia of chronic disease. The parameters of iron profile
serum iron, TIBC, and saturation were not significantly
correlated but the serum ferritin level was significantly
correlated to CD4 counts (p < 0.05). This result was simi-
lar to that reported in the study by Semba et al [14].
In this study we did not find any patient with hemolytic
anaemia. Viral markers were also performed in anaemic
patients None of the infective agents evaluated by serol-
ogy, including EBV, CMV, Parvo B 19 or Hepatitis B were
positive, except for 3 patients positive for Hepatitis C.
These 3 patients had CD4 counts <200 cells/μL and serum
ferritin more than 500 μg/dl which suggests anemia of
chronic disease.
Thrombocytopenia is known to be a frequent complica-
tion of HIV infection (1, 2). The mean platelet count in
our cohort was 239.8 ± 101.3 × 103/μl (range 13.6–685 ×
Table 3: Correlation between parameters and CD4 counts in 200 patients
PARAMETER MEAN ± S.D PEARSON CORRELATION P VALUE
AGE (yrs) 36.66 ± 8.75 (18–60) 0.069 0.330
Hb (gm/dl) 10.3 ± 2.7 (5.1–15.8) 0.660** < 0.001
PCV % 37.2 ± 7.2 (20–68.4) 0.531** < 0.001
MCV (fl) 80.1 ± 8.3 (62.4–103.3) 0.409** < 0.001
MCH (pg/cell) 25.6 ± 4.4 (18.2–36.1) 0.430** < 0.001
MCHC % 31.8 ± 2.7 (26.5–38.4) 0.373** < 0.001
TLC (cells/μl) 6898 ± 2655 (2200–16,000) 0.004 0.952
ANC (cells/μl) 4696 ± 2052 (1012–12848) -0.018 0.802
ALC (cells/μl) 1759 ± 719 (392–4200) 0.046 0.519
PLATELETS (×103 μl) 239.82 ± 101.33 (13.6–685) 0.135 0.056
RETIC % 1.17 ± 0.87 (0.5–5.5) -0.059 0.404
S. IRON (μg/dl) 69.5 ± 52.5 (14–266) -0.076 0.399
TIBC (μg/dl) 399.2 ± 111.3 (155–838) 0.126 0.160
S. FERRITIN (μg/dl) 421 ± 443 (5–1500) -0.213* 0.016
SATURATION% 18.3 ± 13.9 -0.116 0.196
CD4 COUNTS (cells/μl) 202.4 ± 182 (8–1078) 1.0Publish with BioMed Central    and   every 
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103/μl). It had no significant correlation with CD4 counts
confirming to the data with the previous study [10]. Prev-
alence of thrombocytopenia is reported to be higher
among persons with AIDS, older persons, homosexuals
and injecting drug users [15].
We did not detect any case of neutropenia with ANC of
less than 1000 cells/mm3. The result differ from previous
study by Suresh et al in which 22.7% cases had neutrope-
nia [10]. We also did not find any patient with coagula-
tion abnormalities. Bone marrow examination was
carried out in 7% (n = 14) patients. Among 14 patients, 6
each had hypocellular and hypercellular marrow while 2
patients had a normocellular marrow. The bone marrow
trephine biopsy showed epithelioid cell granulomas in 6
patients (4 were positive for AFB, 2 were positive for fun-
gal profiles, morphologically and cytochemically consist-
ent with cryptococci). Hemophagocytosis was
prominently seen in 3 cases, without evidence of any co-
infection. Two patients with lymphoma (NHL) showed
no infiltration by lymphoma cells. HIV infection may lead
to anemia in different ways; the important causes are
defective iron metabolism and reutilization, nutritional
deficiencies, opportunistic infections, ART, administra-
tion of chemotherapeutic agents and advanced stage of
disease with its complications. Therefore, consideration
should be given to monitoring anemia in all HIV-positive
individuals and to offer supplements like iron prepara-
tions, vitamin B12 or folic acid, and in severe cases to pro-
vide erythropoietin treatment or blood transfusions, in
case indicated.
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